TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10758445
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine (4 microg kg‐1) combined with epidural morphine (40 microg kg‐1)
Study: 10758445
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only epidural morphine)
Study: 1304175
Drug: .717% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: .717% fluoride solution
Study: 1304175
Drug: .04% stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: .04% stannous fluoride gel (Gel‐Kam)
Study: 2413097
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg of slow release oxprenolol
Study: 23079770
Drug: Creatine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (10 g daily)
Study: 17593237
Drug: BIAsp30 (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIAsp30 (once daily)
Study: 17593237
Drug: BIAsp30 (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIAsp30 (twice daily)
Study: 17611739
Drug: bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: bromocriptine (2.5 mg)
Study: 12215234
Drug: haloperidol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: haloperidol (2.0 mg)
Study: 9857924
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.1 IU x kg(‐1) week(‐1) for 1 week, then 0.25 IU x kg(‐1) week(‐1) for 3 months)
Study: 7611760
Drug: Tropisetron 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 2.5 mg
Study: 7611760
Drug: Tropisetron 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5.0 mg
Study: 9113121
Drug: Tropisetron 10
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 10 mg
Study: 7611760
Drug: Tropisetron (optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (optimal dose)
Study: 356254
Drug: Hexoprenaline (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexoprenaline (0.20 mg/puff)
Study: 356254
Drug: Terbutaline (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (0.25 mg/puff)
Study: 16364832
Drug: Lactobacillus helveticus
Normalized name: Lactobacillus Helveticus
DrugBank: Lactobacillus helveticus (DB14226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus helveticus LBK‐16H fermented milk (150 mL twice daily for 10 weeks)
Study: 30999969
Drug: HandScan-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandScan-guided treatment aimed at 'HandScan remission' (HandScan arm)
Study: 30999969
Drug: Clinically guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically guided treatment aimed at ACR/EULAR 2011 Boolean remission (DAS arm)
Study: 30999969
Drug: HandScan-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandScan-guided treatment
Study: 30999969
Drug: Clinically guided
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically guided treatment
Study: 24206099
Drug: Atomoxetine (1.0-1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (1.0-1.4 mg/kg/day)
Study: 15168891
Drug: Multivitamins plus
Normalized name: Ferrous Fumarate/Multivitamin Oral Tablet, Chewable [MULTIVITAMINS PLUS IRON CHILDREN'S]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamins plus creatine (amount equal to twice daily creatinine excretion) for four weeks
Study: 8843295
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg daily for 14 days)
Study: 8645788
Drug: Rifabutin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (300 mg daily for 7 or 14 days)
Study: 2083857
Drug: Solution VI
Normalized name: Mitomycin 40 mg powder for intravesical solution vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution VI (glucose 80, sodium 30, potassium 20 mmol/l; 177 mOsm/kg)
Study: 2083857
Drug: Solution II
Normalized name: Balanced Salt Solution Ophthalmic Solution [OCUSOFT IRRIGATING SOLUTION II]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution II (WHO oral rehydration solution; glucose 111, sodium 90, bicarbonate 30, potassium 20; 308 mOsm/kg)
Study: 2083857
Drug: Solution IV
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution IV (glucose 111, sodium 60, potassium 20 mmol/l; 260 mOsm/kg)
Study: 2083857
Drug: Solution III
Normalized name: antithrombin III Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution III (hypertonic commercial oral rehydration solution; glucose 188, sodium 50, bicarbonate 20, potassium 20 mmol/l; 335 mOsm/kg)
Study: 2083857
Drug: Solution V
Normalized name: Flavor Sweet Oral Solution Vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution V (glucose 80, sodium 60, potassium 20 mmol/l; 219 mOsm/kg)
Study: 2083857
Drug: Solution I
Normalized name: SOLUTION IN PACKET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution I (standard cleansing solution; sodium 125, potassium 10, bicarbonate 20, sulphate 40, mannitol 80 mmol/l; 275 mOsm/kg)
Study: 27825893
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 µg ⋅ kg‐1 ⋅ d‐1 intravenous infusion for 48 hours)
Study: 15263050
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and psychotherapy
Study: 9144118
Drug: Rice syrup
Normalized name: Rice Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice syrup solid containing ORS in alternation with rice-based, lactose-free infant formula (Group 2)
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using sumatriptan
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using MK‐462
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using 311C90
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using dihydroergotamine
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using nonsteroidal anti‐inflammatory drugs
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using butorphanol
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using metoclopramide
Study: 8081520
Drug: Acute drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute drug therapy using domperidone
Study: 8081520
Drug: Prophylactic drug
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic drug therapy using valproate
Study: 8081520
Drug: Prophylactic drug
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic drug therapy using fluoxetine
Study: 31948301
Drug: Spinal chiropractic
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal chiropractic manipulative therapy (SCMT)
Study: 1350796
Drug: beta-blocker +
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-blocker + diuretic
Study: 27053407
Drug: ACEI +
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI + diuretic
Study: 27053407
Drug: angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: angiotensin II receptor blocker (ARB) + diuretic
Study: 18706007
Drug: Combined i.v./i.a.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined i.v./i.a. approach to recanalization (lower dose of i.v. rt-PA approximately 0.6 mg/kg, 60 mg maximum over 40 min, followed by angiography and possible i.a. therapy)
Study: 18706007
Drug: Standard i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard i.v. rt-PA alone (full dose 0.9 mg/kg, 90 mg maximum over 1 hour)
Study: 17261975
Drug: Reinstitution or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstitution or continuation of GH therapy
Study: 17261975
Drug: Ongoing GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing GH therapy
Study: 17261975
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of childhood GH replacement therapy without restart in adults
Study: 12663289
Drug: HIGHNAT-E formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIGHNAT-E formula (20 IU RRR-alpha-tocopheryl acetate/L, 14.5 mg/L)
Study: 12663289
Drug: LOWNAT-E formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOWNAT-E formula (10 IU RRR-alpha-tocopheryl acetate/L, 7.3 mg/L)
Study: 12663289
Drug: SYN-E formula
Normalized name: Gel-Syn
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYN-E formula (13.5 IU synthetic all-rac-alpha-tocopheryl acetate/L, 13.5 mg/L)
Study: 10809343
Drug: Oral suspension
Normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral suspension (200 mg phenytoin)
Study: 10809343
Drug: Rectal suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal suppository (200 mg phenytoin)
Study: 8841210
Drug: Standard approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard approach (physician‐chosen combinations of intracervical or vaginal dinoprostone every 6 hours, artificial rupture of membranes, and oxytocin infusion)
Study: 1338088
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg SPFX
Study: 1338088
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg SPFX
Study: 29902542
Drug: Topical spray
Normalized name: Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical spray treatment with 0.005% rhEGF
Study: 21099198
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline spray (placebo)
Study: 19446145
Drug: Flurbiprofen axetil
Normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen axetil 50 mg with tourniquet
Study: 19446145
Drug: Mixed flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mixed flurbiprofen axetil 50 mg and propofol
Study: 2627821
Drug: Cimetidine plus
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine plus antacid (aluminum hydroxide gel)
Study: 180938
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with carmustine (80 mg/sq m/day for three days) and vincristine sulfate (1.4 mg/sq m on days 1 and 8)
Study: 180938
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (4,500 rads whole brain plus 1,500 rads to the side of the tumor)
Study: 23347535
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FO) 15 mL/day for 6 weeks
Study: 23347535
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (OO) 15 mL/day for 6 weeks
Study: 23347535
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (FO) 15 mL/day
Study: 21872376
Drug: Sulodexide 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulodexide 200 mg/d
Study: 17409802
Drug: Docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m2 on days 1, 8, and 15 every 28 days
Study: 17409802
Drug: Docetaxel weekly
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel weekly (30 mg/m2)
Study: 9527193
Drug: High-dose epsilon-aminocaproic
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose epsilon-aminocaproic acid (10 g loading and priming dose, 2.5 g/h until 4 hours after protamine)
Study: 7993957
Drug: BRL 46470
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 46470 (1 mg orally)
Study: 7814826
Drug: mCPP (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.08 mg/kg over 2 min)
Study: 30099
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam, t.i.d.
Study: 30099
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg chlordiazepoxide, t.i.d.
Study: 30099
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment perception
Study: 24609887
Drug: IL-1ra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-1ra (100 mg for 4 weeks)
Study: 20164847
Drug: Amlodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (10 mg/day) + Olmesartan medoxomil (40 mg/day)
Study: 20164847
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil (40 mg/day)
Study: 18058482
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of thioctic acid (ALA) 600 mg
Study: 18058482
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of thioctic acid
Study: 16075942
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (water treatment device with filter and UV light)
Study: 16075942
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (no treatment device)
Study: 12126819
Drug: High-intensity oral
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity oral anticoagulation
Study: 12126819
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose aspirin and moderate intensity oral anticoagulation
Study: 8712395
Drug: 10 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms/kg intravenous (IV) bolus alfentanil
Study: 8712395
Drug: 20 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms/kg intravenous (IV) bolus alfentanil
Study: 1789687
Drug: Octreotide (synthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (synthetic analogue of somatostatin) administered intravenously under double-blind, placebo-controlled conditions.
Study: 1789687
Drug: Octreotide infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide infusion in 6 patients.
Study: 31286476
Drug: Spinal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal sufentanil (5 µg)
Study: 31286476
Drug: Epidural sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural sufentanil (20 µg)
Study: 31286476
Drug: Spinal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Spinal fentanyl (20 µg)
Study: 31286476
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (100 µg)
Study: 15951574
Drug: Dietary advice,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary advice, blood glucose monitoring, and insulin therapy as needed
Study: 7738618
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy with megestrol acetate
Study: 11896093
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy with an aromatase inhibitor (fadrozole or letrozole)
Study: 11896093
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (combined response to both interventions)
Study: 9707853
Drug: Dexamethasone 0.5
Normalized name: dexamethasone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.5 mg/kg/dose 12 hourly for 3 days starting within 6 hours of birth
Study: 7241356
Drug: Tablet (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (50 mg propiram fumarate)
Study: 7241356
Drug: Solution (50
Normalized name: salicylic acid 1 % Topical Solution (50 mL) / salicylic acid 1.5 % Topical Gel (30 mL) / salicylic acid 2 % Medicated Liquid Soap (50 mL) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution (50 mg propiram fumarate)
Study: 7241356
Drug: Tablet and
Normalized name: TABLET AND CAPSULE, DOSE PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet and Solution (comparison)
Study: 21498125
Drug: Dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium 2500 IU s.c. daily, in addition to routine luteal phase support
Study: 7596934
Drug: Captopril (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5 mg bid)
Study: 8934214
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg bid)
Study: 619842
Drug: Therapy plus
Normalized name: Lubriderm Advanced Therapy Plus Ceramide Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy plus drugs
Study: 619842
Drug: Five different
Normalized name: HISTA-FIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five different treatment methods
Study: 12100441
Drug: CQ +
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CQ + SP administered sequentially (CQ0 + SP4)
Study: 12100441
Drug: CQ +
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CQ + SP administered simultaneously (CQ0 + SP0)
Study: 15687338
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - conjugated estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg)
Study: 9915375
Drug: Right half-field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right half-field patches (n = 7)
Study: 9915375
Drug: Right monocular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Right monocular patch (n = 7)
Study: 2110338
Drug: Atropine 1.5
Normalized name: homatropine 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 1.5 mg/70 kg, intramuscularly
Study: 2110338
Drug: Atropine 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 3.0 mg/70 kg, intramuscularly
Study: 2110338
Drug: Atropine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 6.0 mg/70 kg, intramuscularly
Study: 543889
Drug: Ampicillin 3
Normalized name: ampicillin 389 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 3 g + Oxacillin 2 g
Study: 543889
Drug: Ampicillin 2
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 2 g + Oxacillin 1 g
Study: 543889
Drug: Mezlocillin 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 3.75 g + Oxacillin 1.25 g
Study: 543889
Drug: Mezlocillin 2
Normalized name: mezlocillin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mezlocillin 2 g + Oxacillin 1 g
Study: 543889
Drug: Carbenicillin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenicillin 7.5 g + Oxacillin 2.5 g
Study: 543889
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of penicillins
Study: 543889
Drug: Oxacillin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin 2.5 g + Carbenicillin 7.5 g
Study: 30663401
Drug: Adaptive interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adaptive interventions for engaging patients in treatment
Study: 22563197
Drug: Reduced volume
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced volume method (Group A) - did not drink PEG‐ELS the day before; drank 2 L on procedure day.
Study: 22563197
Drug: Conventional volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional volume method (Group B) - drank 2 L PEG‐ELS the day before; drank 1 L on procedure day.
Study: 20207721
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) 15 mg/kg with 100% RDA for SAA
Study: 20207721
Drug: Acetaminophen (APAP)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (APAP) with 0% RDA for SAA
Study: 17684986
Drug: Controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled epidural analgesia (PCEA) with fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 1)
Study: 17684986
Drug: Bolus infections
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus infections of fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 2)
Study: 17684986
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 3)
Study: 9922856
Drug: Trinipatch (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trinipatch (5 mg/24 h and 10 mg/24 h)
Study: 7804442
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (4 mg for adults, 2 mg/m2 for children)
Study: 7804442
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (8 mg for adults, 4 mg for children)
Study: 3051324
Drug: Pancreatic glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pancreatic glucagon (G)